Medigap May Be Elusive for Medicare Beneficiaries with Pre-Existing Conditions

This issue brief analyzes federal and state guaranteed issue rules and how they impact beneficiaries’ access to Medigap, including the implications for Medicare beneficiaries with pre-existing conditions and those under age 65 with long-term disabilities. This brief also explores a recently finalized rule: Nondiscrimination in Health Programs and Activities regarding Section 1557 of the Affordable…

Read More

What makes a drug “special”?

A recent paper by Kacerek and Mattingly (2025) aims to answer why certain drugs are defined as “specialty” drugs and others are not. They first cite an Office of the Inspector General (OIG) report: The OIG found that there was no standard definition in Medicaid and that Medicaid programs used more than 100 different characteristics to…

Read More

Startup Booster Therapeutics Launches to Usher In Next Wave of Protein-Degrading Drugs

Booster Therapeutics’ small molecules activate the 20S proteasome, a component of cells that gets rid of misfolded proteins. Parkinson’s and Alzheimer’s are potential disease targets for the startup, which launched with $15 million in seed financing. The post Startup Booster Therapeutics Launches to Usher In Next Wave of Protein-Degrading Drugs appeared first on MedCity News.

Read More